Trial
NCT02710669
New Formulations of Propafenone to Treat Atrial Fibrillation
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Vanderbilt University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Condition
Atrial Fibrillation
Intervention
(R)-propafenone
Why stopped
Study halted/terminated prematurely due to COVID.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-03